A Pro-Dopaminergic Formulation that Exerts Substantia Nigra Regenerative and Dopaminergic Transmission Enhancing Anti-Parkinson’s Feature Part 2
PART 2 of ANTI-PARKINSON’S FORMULATION WITH SUBSTANTIA NIGRA REGENERATIVE FEATURES In order to achieve the aforesaid advantages, the invention is a composition for treating Parkinson’s disease, said composition being obtained by the components selected from the group comprising methylsalidroside, colforsin 1,9 acetate that are used individually or in combinations. The structural and characteristic features and all the advantages of the invention will become more clearly understood from the detailed description provided below and therefore, the evaluation must be made taking this detailed description into consideration. Detailed Description of the Invention The invention is a composition formed for the use of methylsalidroside and colforsin derivatives in the treatment of Parkinson’s disease. Methylsalidroside, one of the ingredients of the composition according to the invention, is a glucoside derivative naturally contained in trace amount by the plant rhodiola rosea. This ingredient, with the capability of providing stimulation in Substantia Nigra, both triggers the release of dopamine and preserves the dopaminergic receptor sensitivity. This ingredient, which also suppresses the conversion of dopamine to adrenaline, thus provides an effective pro-dopaminergic action. Colforsin is a labdane diterpene naturally contained by the plants belonging to the family Coleus. It stimulates the adenasyl cyclase enzyme to increase the cAMP level. Colforsin also provides a neurotrophic effect owing to the elevation it provides in the level of cAMP. Colforsin, another ingredient of the invention, stimulates the renewal of the nerve cells in substantia nigra. Colforsin increases the expression of NGF (nerve growth factor). Colforsin also supports the axone function. Colforsin accelerates and promotes the dendrite formation. The two ingredients exhibit a synergistic action together and provide an effective therapeutic characteristic both for the symptoms caused by Parkinson’s disease and for the cause of the disease itself. The composition according to the invention contains methylsalidroside, colforsin 1,9 acetate. Said formulation is obtained by a mixture of the aforesaid components according to the following ratios by weight: 99-1% methylsalidroside, 1-99% colforsin 1,9 acetate. The composition is obtained from the aforesaid components selected from the aforesaid group and used according to the mentioned weight ratio ranges individually or in combinations. Said invention also encompasses the use of said composition for treating Parkinson’s disease and the manufacture thereof for this purpose. CLAIMS 1. A composition for treating Parkinson’s disease, said composition being obtained by the components selected from the group comprising methylsalidroside, colforsin 1,9 acetate that are used individually or in combinations. 2. A composition according to Claim 1 characterized in that it comprises 99-1% by weight methylsalidroside. 3. A composition according to Claim 1 characterized in that it comprises 1-99% by weight colforsin 1,9 acetate. 4. Use of the components according to Claims 1 to 3 obtained individually or in combinations from the group consisting of methylsalidroside, colforsin 1,9 acetate for the manufacture of a composition for treating Parkinson’s disease. ABSTRACT A COMPOSITION FOR THE TREATMENT OF PARKINSON’S DISEASE The invention relates to a composition formed for the treatment of Parkinson’s disease. Invented by Erdal Can Alkoclar & Metehan Yesil